Race Oncology Ltd. (AU:RAC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. has submitted the necessary regulatory documents for a Phase 1 clinical trial of their RC220 bisantrene treatment, aimed at combating solid tumors. This trial will explore the safety and efficacy of RC220 in combination with doxorubicin, with patient recruitment expected to begin in Q1 2025. The study, which will take place across multiple sites in Australia, Hong Kong, and South Korea, could pave the way for larger international trials, enhancing treatment options for cancer patients.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.